Wockhardt gets US FDA’s approval for marketing Fluticasone nasal spray

10 Jan 2012 Evaluate

Wockhardt, a pharmaceutical and biotechnology major has received final approval from United States Food and Drug Administration (US FDA) for marketing 50 mcg nasal spray of Fluticasone which is used in treatment of allergic rhinitis. Fluticasone nasal spray is the generic name for the brand Flonase, marketed in the US by Glaxo Smithkline. The company is launching the product immediately.

The total market for this product in the US is about $580 million and there are only three other generic version of the product in the United States. Fluticasone nasal spray is amongst the most widely used corticosteroids in treating allergic rhinitis.

Wockhardt will be manufacturing the nasal spray at its facility in Morton Grove, Illinois, USA. The technology for this nasal spray was developed in-house.

Wockhardt Share Price

1466.70 5.55 (0.38%)
27-Dec-2024 13:30 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1862.15
Dr. Reddys Lab 1394.55
Cipla 1510.65
Lupin 2229.60
Zydus Lifesciences 979.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.